Interesting company, and with the increasing prevalence of melanoma, the market should grow. I personally held a small position in this, but those warrants seem to prevent a larger price increase. In addition, revenue growth has been so slow that a new share issue (and more warrants) might be on the horizon again by the end of the year. The number of employees has now slightly increased, apparently the US sales organization has been strengthened?
3 Likes